Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry st...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2019-05-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/25/5/18-1823_article |
| _version_ | 1818912120104812544 |
|---|---|
| author | Lawrence Mbuagbaw Lorenzo Guglielmetti Catherine Hewison Nyasha Bakare Mathieu Bastard Eric Caumes Mathilde Fréchet-Jachym Jérôme Robert Nicolas Veziris Naira Khachatryan Tinatin Kotrikadze Armen Hayrapetyan Zaza Avaliani Holger J. Schünemann Christian Lienhardt |
| author_facet | Lawrence Mbuagbaw Lorenzo Guglielmetti Catherine Hewison Nyasha Bakare Mathieu Bastard Eric Caumes Mathilde Fréchet-Jachym Jérôme Robert Nicolas Veziris Naira Khachatryan Tinatin Kotrikadze Armen Hayrapetyan Zaza Avaliani Holger J. Schünemann Christian Lienhardt |
| author_sort | Lawrence Mbuagbaw |
| collection | DOAJ |
| description | Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.5%–81.9%), and the treatment success rate was 65.8% (95% CI 59.9%–71.3%). Death rate was 11.7% (95% CI 7.0%–19.1%). Up to 91.1% (95% CI 82.2%–95.8%) of the patients experienced >1 adverse event, and 11.2% (95% CI 5.0%–23.2%) experienced a serious adverse event. Lung cavitations were consistently associated with unfavorable outcomes. The use of bedaquiline in MDR and XDR TB treatment regimens appears to be effective and safe across different settings, although the certainty of evidence was assessed as very low. |
| first_indexed | 2024-12-19T23:09:32Z |
| format | Article |
| id | doaj.art-aca51c7af9fb4ceb917fdc54305dfd56 |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-12-19T23:09:32Z |
| publishDate | 2019-05-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-aca51c7af9fb4ceb917fdc54305dfd562022-12-21T20:02:17ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592019-05-0125593694310.3201/eid2505.181823Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant TuberculosisLawrence MbuagbawLorenzo GuglielmettiCatherine HewisonNyasha BakareMathieu BastardEric CaumesMathilde Fréchet-JachymJérôme RobertNicolas VezirisNaira KhachatryanTinatin KotrikadzeArmen HayrapetyanZaza AvalianiHolger J. SchünemannChristian LienhardtBedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.5%–81.9%), and the treatment success rate was 65.8% (95% CI 59.9%–71.3%). Death rate was 11.7% (95% CI 7.0%–19.1%). Up to 91.1% (95% CI 82.2%–95.8%) of the patients experienced >1 adverse event, and 11.2% (95% CI 5.0%–23.2%) experienced a serious adverse event. Lung cavitations were consistently associated with unfavorable outcomes. The use of bedaquiline in MDR and XDR TB treatment regimens appears to be effective and safe across different settings, although the certainty of evidence was assessed as very low.https://wwwnc.cdc.gov/eid/article/25/5/18-1823_articlemultidrug resistantextensively drug resistanttuberculosisbedaquilineindividual patient datatuberculosis and other mycobacteria |
| spellingShingle | Lawrence Mbuagbaw Lorenzo Guglielmetti Catherine Hewison Nyasha Bakare Mathieu Bastard Eric Caumes Mathilde Fréchet-Jachym Jérôme Robert Nicolas Veziris Naira Khachatryan Tinatin Kotrikadze Armen Hayrapetyan Zaza Avaliani Holger J. Schünemann Christian Lienhardt Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis Emerging Infectious Diseases multidrug resistant extensively drug resistant tuberculosis bedaquiline individual patient data tuberculosis and other mycobacteria |
| title | Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis |
| title_full | Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis |
| title_fullStr | Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis |
| title_full_unstemmed | Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis |
| title_short | Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis |
| title_sort | outcomes of bedaquiline treatment in patients with multidrug resistant tuberculosis |
| topic | multidrug resistant extensively drug resistant tuberculosis bedaquiline individual patient data tuberculosis and other mycobacteria |
| url | https://wwwnc.cdc.gov/eid/article/25/5/18-1823_article |
| work_keys_str_mv | AT lawrencembuagbaw outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT lorenzoguglielmetti outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT catherinehewison outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT nyashabakare outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT mathieubastard outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT ericcaumes outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT mathildefrechetjachym outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT jeromerobert outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT nicolasveziris outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT nairakhachatryan outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT tinatinkotrikadze outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT armenhayrapetyan outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT zazaavaliani outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT holgerjschunemann outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis AT christianlienhardt outcomesofbedaquilinetreatmentinpatientswithmultidrugresistanttuberculosis |